Your browser is no longer supported. Please, upgrade your browser.
Settings
AGEN [NASD]
Agenus Inc.
Index- P/E- EPS (ttm)-1.09 Insider Own0.20% Shs Outstand182.67M Perf Week-8.55%
Market Cap769.94M Forward P/E- EPS next Y-1.06 Insider Trans0.00% Shs Float173.55M Perf Month7.90%
Income-173.60M PEG- EPS next Q-0.22 Inst Own56.50% Short Float13.72% Perf Quarter12.82%
Sales91.40M P/S8.42 EPS this Y44.60% Inst Trans4.48% Short Ratio8.30 Perf Half Y-1.74%
Book/sh-1.09 P/B- EPS next Y0.90% ROA-95.70% Target Price- Perf Year56.52%
Cash/sh0.59 P/C6.75 EPS next 5Y- ROE82.80% 52W Range1.82 - 5.95 Perf YTD24.53%
Dividend- P/FCF- EPS past 5Y-2.30% ROI- 52W High-33.45% Beta1.68
Dividend %- Quick Ratio- Sales past 5Y84.70% Gross Margin98.30% 52W Low117.58% ATR0.31
Employees328 Current Ratio0.90 Sales Q/Q-25.60% Oper. Margin- RSI (14)41.45 Volatility4.72% 8.12%
OptionableYes Debt/Eq- EPS Q/Q15.30% Profit Margin- Rel Volume0.77 Prev Close4.00
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume2.87M Price3.96
Recom1.30 SMA20-12.48% SMA502.36% SMA2003.58% Volume2,218,723 Change-1.00%
Nov-19-19Resumed B. Riley FBR Buy $6
Apr-22-19Initiated B. Riley FBR Buy
Oct-28-16Downgrade H.C. Wainwright Buy → Neutral $10 → $5
Oct-27-16Reiterated Maxim Group Buy
Mar-11-16Upgrade Maxim Group Hold → Buy $7
Dec-16-15Initiated Jefferies Buy
Oct-27-15Downgrade Maxim Group Buy → Hold
Jul-27-15Reiterated MLV & Co Buy $9 → $11
Jun-11-15Initiated Oppenheimer Outperform $14
Jan-12-15Reiterated Maxim Group Buy $10 → $11
Jan-09-15Reiterated MLV & Co Buy $6 → $9
Jan-09-15Reiterated Maxim Group Buy $10 → $11
Dec-19-14Reiterated Maxim Group Buy $8 → $10
May-08-14Reiterated Maxim Group Buy $17 → $11
Mar-14-14Reiterated MLV & Co Buy $9 → $11
Oct-08-13Reiterated Maxim Group Buy $19
Jan-05-12Initiated William Blair Outperform
Dec-01-11Initiated Global Hunter Securities Buy $6
Feb-09-21 05:06PM  
11:00AM  
08:45AM  
Feb-05-21 07:43AM  
Feb-04-21 08:30AM  
Jan-31-21 01:00AM  
Jan-26-21 08:30AM  
Jan-19-21 12:09PM  
Dec-13-20 09:44PM  
Dec-03-20 07:45AM  
Dec-01-20 08:00AM  
Nov-25-20 01:28PM  
Nov-16-20 07:04PM  
Nov-13-20 02:43PM  
Nov-12-20 09:00AM  
Nov-11-20 07:30AM  
Nov-10-20 08:45AM  
Nov-09-20 08:15AM  
Nov-05-20 08:00AM  
Nov-02-20 02:39PM  
08:45AM  
05:02AM  
Oct-30-20 03:30AM  
Oct-29-20 09:05AM  
07:45AM  
06:30AM  
Oct-22-20 12:33PM  
Oct-20-20 10:34AM  
Oct-14-20 05:00PM  
Oct-13-20 08:30AM  
Oct-01-20 07:13AM  
Sep-21-20 12:58PM  
Sep-18-20 10:13AM  
08:30AM  
03:00AM  
Sep-17-20 05:06PM  
01:38PM  
Sep-11-20 10:28AM  
Sep-10-20 02:27PM  
Aug-31-20 08:00AM  
Aug-27-20 03:30PM  
Aug-26-20 02:46PM  
Aug-19-20 08:30AM  
Aug-06-20 11:55AM  
Aug-05-20 12:00PM  
Jul-21-20 01:31PM  
Jul-13-20 12:00PM  
Jul-05-20 03:40PM  
Jul-03-20 10:25AM  
06:31AM  
Jun-26-20 12:00PM  
Jun-25-20 11:30AM  
08:47AM  
Jun-24-20 04:53PM  
12:35PM  
Jun-23-20 10:34AM  
Jun-22-20 09:43AM  
07:00AM  
Jun-17-20 11:06AM  
10:53AM  
Jun-16-20 08:12AM  
Jun-08-20 02:32PM  
09:56AM  
Jun-06-20 11:31AM  
Jun-05-20 12:37AM  
Jun-03-20 07:39AM  
Jun-02-20 11:30AM  
08:30AM  
Jun-01-20 09:21AM  
May-29-20 01:28PM  
09:43AM  
08:00AM  
May-28-20 09:42AM  
09:10AM  
May-26-20 05:47PM  
May-14-20 11:56AM  
08:00AM  
May-13-20 09:54AM  
09:43AM  
May-11-20 12:00PM  
May-08-20 07:30PM  
May-07-20 09:35AM  
08:29AM  
08:00AM  
Apr-30-20 12:34PM  
Apr-28-20 11:50AM  
Apr-16-20 08:56AM  
08:38AM  
Apr-07-20 01:04PM  
Apr-06-20 09:00AM  
Mar-24-20 12:00PM  
Mar-16-20 06:09AM  
Mar-13-20 11:57AM  
Mar-12-20 10:05AM  
07:45AM  
07:30AM  
Mar-10-20 09:14AM  
Mar-05-20 12:30PM  
Mar-03-20 08:00AM  
Feb-28-20 08:58AM  
Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGF TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
INCYTE CORP10% OwnerJun 17Sale3.66141,920518,83116,972,968Jun 18 05:30 PM
INCYTE CORP10% OwnerJun 16Sale3.6672,080264,00717,114,888Jun 18 05:30 PM
INCYTE CORP10% OwnerJun 15Sale3.57384,0251,372,16017,186,968Jun 15 08:47 PM
INCYTE CORP10% OwnerJun 12Sale3.589,10032,55617,570,993Jun 15 08:47 PM
INCYTE CORP10% OwnerJun 11Sale3.77183,875692,78617,580,093Jun 15 08:47 PM
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E- EPS (ttm)-4.02 Insider Own0.10% Shs Outstand2.25B Perf Week1.05%
Market Cap139.81B Forward P/E7.66 EPS next Y8.05 Insider Trans-5.49% Shs Float2.22B Perf Month-1.06%
Income-9015.00M PEG- EPS next Q1.83 Inst Own76.00% Short Float0.94% Perf Quarter-1.93%
Sales42.52B P/S3.29 EPS this Y-298.80% Inst Trans-0.41% Short Ratio1.76 Perf Half Y-1.41%
Book/sh16.79 P/B3.67 EPS next Y7.57% ROA-7.20% Target Price75.13 Perf Year4.35%
Cash/sh6.98 P/C8.83 EPS next 5Y21.35% ROE-19.30% 52W Range45.76 - 67.16 Perf YTD-0.64%
Dividend1.96 P/FCF15.16 EPS past 5Y-44.40% ROI-12.10% 52W High-8.23% Beta0.62
Dividend %3.18% Quick Ratio1.50 Sales past 5Y20.80% Gross Margin73.80% 52W Low34.68% ATR1.35
Employees30250 Current Ratio1.60 Sales Q/Q39.30% Oper. Margin-20.30% RSI (14)50.22 Volatility2.21% 2.08%
OptionableYes Debt/Eq1.34 EPS Q/Q-708.70% Profit Margin-21.20% Rel Volume0.62 Prev Close61.33
ShortableYes LT Debt/Eq1.28 EarningsFeb 04 BMO Payout- Avg Volume11.84M Price61.63
Recom1.90 SMA201.00% SMA50-1.09% SMA2001.13% Volume7,318,500 Change0.49%
Nov-16-20Upgrade Societe Generale Hold → Buy $76
Nov-10-20Resumed Bernstein Mkt Perform
Nov-06-20Downgrade Gabelli & Co Buy → Hold
Oct-19-20Upgrade Guggenheim Neutral → Buy $70
Sep-29-20Initiated Berenberg Buy $73
Jul-28-20Initiated Raymond James Outperform $75
Apr-02-20Upgrade Morgan Stanley Equal-Weight → Overweight $64
Mar-23-20Downgrade Societe Generale Buy → Hold $50
Feb-27-20Initiated Barclays Equal Weight $69
Jan-06-20Resumed Citigroup Buy $73
Dec-13-19Upgrade Argus Hold → Buy $80
Nov-22-19Resumed Morgan Stanley Equal-Weight $60
Oct-17-19Resumed BofA/Merrill Buy $60
Aug-14-19Upgrade Atlantic Equities Neutral → Overweight $63
May-28-19Initiated Goldman Buy
May-20-19Downgrade Argus Buy → Hold
May-03-19Upgrade Barclays Equal Weight → Overweight $53 → $55
May-03-19Resumed JP Morgan Overweight $62
Jan-15-19Upgrade Societe Generale Sell → Buy
Oct-22-18Downgrade Citigroup Buy → Neutral
Mar-01-21 04:22PM  
04:16PM  
05:51AM  
Feb-26-21 09:21AM  
07:45AM  
06:25AM  
Feb-24-21 12:15PM  
09:31AM  
08:07AM  
07:10AM  
06:59AM  
Feb-23-21 09:00AM  
06:59AM  
Feb-22-21 06:15PM  
04:38PM  
Feb-20-21 12:01PM  
07:00AM  
Feb-19-21 05:04PM  
Feb-18-21 09:29PM  
Feb-17-21 04:19PM  
12:06PM  
06:54AM  
Feb-16-21 06:26PM  
12:13PM  
06:30AM  
Feb-15-21 11:00PM  
08:29PM  
06:16PM  
Feb-12-21 02:14PM  
Feb-11-21 09:13AM  
09:13AM  
Feb-10-21 05:19PM  
10:49AM  
Feb-09-21 04:22PM  
11:14AM  
10:19AM  
09:22AM  
08:15AM  
Feb-08-21 07:24PM  
05:00PM  
05:00PM  
12:12PM  
11:04AM  
Feb-07-21 08:35AM  
Feb-05-21 04:39PM  
04:17PM  
06:59AM  
06:06AM  
02:01AM  
Feb-04-21 06:00PM  
05:56PM  
04:56PM  
04:38PM  
04:31PM  
04:20PM  
04:10PM  
12:47PM  
12:00PM  
11:39AM  
11:04AM  
10:11AM  
09:50AM  
08:30AM  
08:25AM  
07:45AM  
07:21AM  
07:18AM  
06:59AM  
06:59AM  
06:30AM  
03:33AM  
02:08AM  
Feb-03-21 11:42AM  
06:59AM  
06:02AM  
Feb-02-21 06:59AM  
06:59AM  
06:06AM  
05:50AM  
Feb-01-21 01:05PM  
10:46AM  
07:50AM  
06:59AM  
Jan-28-21 04:40PM  
12:32PM  
10:50AM  
Jan-25-21 05:45PM  
Jan-24-21 10:30AM  
06:45AM  
05:51AM  
Jan-22-21 01:18PM  
12:10PM  
07:50AM  
Jan-21-21 08:00AM  
06:59AM  
Jan-20-21 06:59AM  
06:59AM  
Jan-18-21 04:10PM  
Jan-15-21 05:45PM  
12:19PM  
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; and Nektar Therapeutics. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VESSEY RUPERTEVP, Research & Early Dev.Feb 04Option Exercise0.003,592058,409Feb 08 07:28 PM
Elkins David VEVP, Chief Financial OfficerDec 31Option Exercise0.0020,624079,111Jan 05 08:13 PM
VESSEY RUPERTEVP, Research & Early Dev.Dec 31Option Exercise0.0025,866068,074Jan 05 08:14 PM
AHMED NADIMEVP and President, HematologyDec 31Option Exercise0.0014,946046,549Jan 05 08:13 PM
Elkins David VEVP, Chief Financial OfficerDec 02Option Exercise0.008,792063,574Dec 03 08:24 PM
AHMED NADIMEVP and President, HematologyDec 02Option Exercise0.006,594034,983Dec 03 08:24 PM
VESSEY RUPERTEVP, Research & Early Dev.Dec 02Option Exercise0.008,792046,714Dec 03 08:24 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerDec 02Option Exercise0.002,637023,670Dec 03 08:23 PM
Eid JosephSVP,Head Glob. Medical AffairsDec 01Option Exercise0.002,82505,359Dec 03 05:15 PM
von Autenried PaulEVP, Chief Information OfficerNov 25Sale63.503191126,698Nov 30 05:52 PM
von Autenried PaulEVP, Chief Information OfficerNov 24Sale62.7520,0001,255,000126,701Nov 25 04:31 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.Nov 24Sale63.3990057,05115,186Nov 25 04:32 PM
VESSEY RUPERTEVP, Research & Early Dev.Nov 23Sale61.3413,421823,24437,922Nov 25 04:32 PM
VESSEY RUPERTEVP, Research & Early Dev.Nov 19Option Exercise49.2852,2132,572,88798,355Nov 23 05:40 PM
VESSEY RUPERTEVP, Research & Early Dev.Nov 19Sale61.3057,5913,530,26946,142Nov 23 05:40 PM
AHMED NADIMEVP and President, HematologyOct 30Option Exercise0.004,650030,680Nov 03 04:28 PM
VESSEY RUPERTEVP, Research & Early Dev.Oct 30Option Exercise0.005,804059,580Nov 03 04:27 PM
Santiago Karen MurphySVP & ControllerSep 01Option Exercise0.0064208,390Sep 02 04:33 PM
Caforio GiovanniChairman and CEOAug 31Sale62.7039,8402,497,968445,584Sep 02 04:34 PM
Eid JosephSVP,Head Glob. Medical AffairsAug 17Sale64.005,327340,9282,534Aug 19 06:15 PM
LEUNG SANDRAEVP, General CounselAug 13Sale63.24141,4208,943,401432,744Aug 17 04:55 PM
Elkins David VEVP, Chief Financial OfficerAug 01Option Exercise0.0046,402080,698Aug 04 04:43 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Jul 01Option Exercise0.009,35609,356Jul 02 04:56 PM
Santiago Karen MurphySVP & ControllerJul 01Option Exercise0.001,06908,115Jul 02 04:54 PM
Paliwal Dinesh CDirectorJun 15Buy54.509,174499,98322,109Jun 16 05:15 PM
BONNEY MICHAEL WDirectorJun 14Option Exercise0.0055808,650Jun 16 05:16 PM
Haller Julia ADirectorJun 14Option Exercise0.0055806,819Jun 16 05:15 PM
Haller Julia ADirectorJun 13Option Exercise0.0090306,261Jun 16 05:15 PM
BONNEY MICHAEL WDirectorJun 13Option Exercise0.0090308,092Jun 16 05:16 PM
Haller Julia ADirectorJun 03Option Exercise0.002,94905,358Jun 05 04:39 PM
BONNEY MICHAEL WDirectorJun 03Option Exercise0.002,94907,189Jun 05 04:40 PM
Eid JosephSVP,Head Glob. Medical AffairsJun 03Option Exercise0.002,15408,599Jun 09 07:15 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.May 22Sale61.013,200195,23216,086May 26 05:17 PM
Schmukler Louis SEVP,Pres.,Glob.Prod. & SupplyMay 19Sale62.6825,0001,567,00026,777May 21 05:22 PM
VESSEY RUPERTEVP, Research & Early Dev.May 01Option Exercise0.0010,707059,050May 05 04:49 PM
AHMED NADIMEVP and President, HematologyMay 01Option Exercise0.002,908027,463May 05 04:49 PM
Schmukler Louis SEVP,Pres.,Glob.Prod. & SupplyMar 10Option Exercise0.0030,519058,379Mar 12 06:18 PM
von Autenried PaulEVP, Chief Information OfficerMar 10Option Exercise0.0020,8060152,400Mar 12 06:19 PM
Powell AnnEVP, Chief Human ResourcesMar 10Option Exercise0.0031,169058,421Mar 12 06:17 PM
Santiago Karen MurphyControllerMar 10Option Exercise0.005,06307,778Mar 12 06:17 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0051,5980588,175Mar 12 06:15 PM
Eid JosephSVP,Head Glob. Medical AffairsMar 10Option Exercise0.001,57106,652Mar 12 06:13 PM
Elicker John EEVP, Investor RelationsMar 10Option Exercise0.0018,407075,102Mar 12 06:14 PM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00211,7960544,032Mar 12 06:11 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.Mar 10Option Exercise0.005,007020,091Mar 12 06:12 PM
Bancroft Charles AEVP, Head of IntegrationMar 10Option Exercise0.0071,8680153,637Mar 12 06:11 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerMar 10Option Exercise0.0021,426026,091Mar 12 06:11 PM
Elicker John EEVP, Investor RelationsMar 04Sale61.0115,805964,26358,666Mar 06 05:20 PM
VESSEY RUPERTPres., Research & Early Dev.Mar 02Option Exercise51.6993,4684,831,452132,651Mar 04 06:19 PM
VESSEY RUPERTPres., Research & Early Dev.Mar 02Sale60.5984,3085,108,22248,343Mar 04 06:19 PM
DVAX Dynavax Technologies Corporation daily Stock Chart
DVAX [NASD]
Dynavax Technologies Corporation
Index- P/E- EPS (ttm)-1.08 Insider Own0.10% Shs Outstand110.25M Perf Week-7.29%
Market Cap914.39M Forward P/E- EPS next Y-0.35 Insider Trans-29.09% Shs Float109.38M Perf Month50.85%
Income-96.50M PEG- EPS next Q-0.19 Inst Own76.90% Short Float19.39% Perf Quarter109.41%
Sales37.60M P/S24.32 EPS this Y77.30% Inst Trans-4.71% Short Ratio3.48 Perf Half Y48.33%
Book/sh0.53 P/B16.79 EPS next Y-100.00% ROA- Target Price- Perf Year125.60%
Cash/sh1.61 P/C5.54 EPS next 5Y- ROE- 52W Range1.80 - 12.44 Perf YTD100.00%
Dividend- P/FCF- EPS past 5Y- ROI-28.70% 52W High-28.46% Beta1.29
Dividend %- Quick Ratio2.90 Sales past 5Y63.00% Gross Margin61.20% 52W Low394.44% ATR1.08
Employees231 Current Ratio3.70 Sales Q/Q84.90% Oper. Margin- RSI (14)53.14 Volatility11.87% 14.06%
OptionableYes Debt/Eq3.06 EPS Q/Q- Profit Margin- Rel Volume0.58 Prev Close8.75
ShortableNo LT Debt/Eq3.06 EarningsFeb 25 AMC Payout- Avg Volume6.09M Price8.90
Recom1.70 SMA20-6.09% SMA5029.51% SMA20043.18% Volume3,520,620 Change1.71%
Aug-07-20Reiterated H.C. Wainwright Buy $14 → $12
Aug-03-20Reiterated H.C. Wainwright Buy $12 → $14
Jun-15-20Initiated Evercore ISI Outperform $14
Oct-18-19Initiated H.C. Wainwright Buy $13
Jul-11-19Upgrade Cantor Fitzgerald Neutral → Overweight $20
Feb-27-19Reiterated Cantor Fitzgerald Overweight $32 → $28
May-10-18Upgrade JP Morgan Neutral → Overweight
Mar-08-18Reiterated Cantor Fitzgerald Overweight $25 → $27
Feb-14-18Downgrade JP Morgan Overweight → Neutral
Sep-25-17Reiterated RBC Capital Mkts Outperform $26 → $28
Sep-15-17Initiated Cantor Fitzgerald Overweight $24
Jul-31-17Upgrade RBC Capital Mkts Sector Perform → Outperform $7 → $26
Jul-31-17Upgrade JP Morgan Neutral → Overweight
May-09-17Reiterated RBC Capital Mkts Sector Perform $6 → $7
Apr-28-16Downgrade RBC Capital Mkts Outperform → Sector Perform $48 → $17
Apr-27-16Downgrade JP Morgan Overweight → Neutral
Nov-30-15Initiated RBC Capital Mkts Outperform $48
Nov-25-13Upgrade MLV & Co Hold → Buy $1.50 → $5
Feb-25-13Downgrade MLV & Co Buy → Hold
Nov-16-12Reiterated MLV & Co Buy $10 → $7.50
Mar-01-21 04:15PM  
04:14PM  
Feb-26-21 11:00AM  
06:00AM  
05:01AM  
Feb-25-21 02:30PM  
Feb-24-21 10:04AM  
Feb-21-21 04:58AM  
Feb-19-21 03:33PM  
12:20PM  
Feb-16-21 04:05PM  
Feb-11-21 04:05PM  
Feb-09-21 08:09AM  
Feb-08-21 04:13PM  
10:11AM  
Feb-04-21 04:05PM  
11:03AM  
08:00AM  
Feb-02-21 03:33PM  
Feb-01-21 11:24PM  
01:15PM  
10:35AM  
07:02AM  
07:01AM  
07:00AM  
Jan-28-21 07:05AM  
Jan-25-21 08:00AM  
Jan-21-21 08:05AM  
Jan-20-21 04:05PM  
Jan-08-21 06:02AM  
Jan-07-21 12:13PM  
08:00AM  
Jan-06-21 04:05PM  
Dec-23-20 08:00AM  
Dec-11-20 11:42AM  
08:11AM  
Dec-10-20 04:05PM  
Dec-04-20 03:00AM  
Nov-17-20 04:05PM  
Nov-16-20 06:00AM  
Nov-10-20 05:33AM  
Nov-07-20 08:58AM  
Nov-06-20 07:33AM  
03:01AM  
Nov-05-20 06:35PM  
04:01PM  
02:45PM  
Nov-03-20 09:56AM  
Nov-02-20 04:05PM  
Oct-30-20 08:14AM  
Oct-29-20 12:35PM  
Oct-27-20 05:50PM  
Oct-22-20 04:05PM  
Oct-21-20 05:50PM  
Oct-19-20 03:30PM  
Oct-13-20 07:09AM  
06:00AM  
Oct-07-20 10:00AM  
Oct-02-20 05:50PM  
Sep-24-20 04:05PM  
Sep-15-20 08:58AM  
Sep-14-20 09:53AM  
01:00AM  
Sep-08-20 03:14PM  
Sep-07-20 11:08AM  
Sep-05-20 08:02AM  
Aug-31-20 04:10PM  
Aug-13-20 08:00AM  
Aug-12-20 12:12PM  
10:07AM  
Aug-11-20 11:27AM  
09:14AM  
Aug-10-20 08:38AM  
Aug-06-20 08:20PM  
04:02PM  
Aug-05-20 11:56AM  
Aug-03-20 03:53PM  
08:00AM  
Jul-30-20 04:05PM  
Jul-29-20 12:33PM  
Jul-28-20 08:19AM  
Jul-27-20 10:53AM  
Jul-23-20 05:50PM  
08:00AM  
Jul-21-20 04:10PM  
04:10PM  
Jul-17-20 11:42AM  
11:23AM  
05:29AM  
Jul-16-20 10:02AM  
08:40AM  
Jul-14-20 11:28AM  
08:00AM  
08:00AM  
Jul-13-20 05:45PM  
Jul-10-20 04:01PM  
Jul-08-20 10:09AM  
08:30AM  
Jul-07-20 09:43AM  
08:23AM  
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of Queensland and the Coalition for Epidemic Preparedness; and Sinovac Biotech Ltd. for the development of a vaccine candidate to prevent coronavirus (COVID-19). Dynavax Technologies Corporation has partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against COVID-19 infection; a collaboration with Valneva SE to initiate a vaccine program for the coronavirus, COVID-19; and collaboration with Medicago to develop a novel adjuvanted COVID 19 vaccine candidate. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Janssen RobertSenior Vice PresidentFeb 01Sale10.6442,155448,52986,485Feb 03 06:28 PM
Janssen RobertSenior Vice PresidentJul 17Sale11.0950,000554,500127,266Jul 20 07:42 PM
Hack Andrew A. F.DirectorMay 27Buy5.001,000,0005,000,0008,525,000May 28 05:13 PM
Janssen RobertSenior Vice PresidentMay 19Sale6.3315,00094,950177,266May 19 07:05 PM
Janssen RobertSenior Vice PresidentMay 06Sale4.5228,000126,560192,266May 07 06:37 PM
Janssen RobertSenior Vice PresidentMay 05Sale4.439,00039,870220,266May 07 06:37 PM
GSK GlaxoSmithKline plc daily Stock Chart
GSK [NYSE]
GlaxoSmithKline plc
Index- P/E10.52 EPS (ttm)3.21 Insider Own0.20% Shs Outstand2.49B Perf Week-2.06%
Market Cap86.81B Forward P/E10.69 EPS next Y3.16 Insider Trans0.00% Shs Float2.45B Perf Month-11.31%
Income8.06B PEG2.24 EPS next Q- Inst Own11.80% Short Float0.79% Perf Quarter-9.40%
Sales47.78B P/S1.82 EPS this Y31.60% Inst Trans1.77% Short Ratio3.52 Perf Half Y-15.14%
Book/sh8.04 P/B4.20 EPS next Y9.17% ROA8.10% Target Price46.57 Perf Year-16.78%
Cash/sh2.38 P/C14.19 EPS next 5Y4.70% ROE51.00% 52W Range31.43 - 43.38 Perf YTD-8.34%
Dividend2.11 P/FCF13.64 EPS past 5Y10.30% ROI14.30% 52W High-22.25% Beta0.67
Dividend %6.26% Quick Ratio0.60 Sales past 5Y8.00% Gross Margin68.10% 52W Low7.32% ATR0.58
Employees99437 Current Ratio0.90 Sales Q/Q-7.90% Oper. Margin26.10% RSI (14)30.95 Volatility1.31% 1.34%
OptionableYes Debt/Eq1.98 EPS Q/Q-20.40% Profit Margin19.60% Rel Volume0.99 Prev Close33.61
ShortableYes LT Debt/Eq1.63 EarningsFeb 03 BMO Payout10.10% Avg Volume5.51M Price33.73
Recom2.00 SMA20-4.75% SMA50-8.09% SMA200-12.58% Volume5,467,433 Change0.36%
Feb-04-21Downgrade Deutsche Bank Hold → Sell
Jan-20-21Downgrade Credit Suisse Neutral → Underperform
Jan-15-21Initiated Deutsche Bank Hold
Nov-02-20Upgrade Liberum Hold → Buy
Sep-29-20Initiated Berenberg Buy
Feb-12-20Downgrade Shore Capital Hold → Sell
Jan-16-20Downgrade Barclays Equal Weight → Underweight
Dec-02-19Initiated SVB Leerink Outperform
Nov-21-19Upgrade UBS Neutral → Buy
Oct-11-19Upgrade Cantor Fitzgerald Hold → Buy
Sep-03-19Upgrade Societe Generale Sell → Buy
Sep-03-19Resumed Citigroup Neutral
Aug-13-19Resumed JP Morgan Neutral
Jun-17-19Resumed Morgan Stanley Underweight
Mar-08-19Downgrade Shore Capital Buy → Hold
Feb-22-19Downgrade UBS Buy → Neutral
Jan-14-19Downgrade Exane BNP Paribas Outperform → Neutral
Dec-11-18Resumed Jefferies Buy
Oct-09-18Initiated Guggenheim Neutral
Aug-30-18Downgrade Liberum Buy → Hold
Mar-01-21 02:58PM  
01:45PM  
08:00AM  
Feb-26-21 06:55PM  
01:16PM  
10:06AM  
Feb-25-21 02:39PM  
02:13PM  
11:26AM  
10:20AM  
07:00AM  
Feb-24-21 09:31AM  
Feb-22-21 05:23PM  
08:01AM  
07:14AM  
06:23AM  
06:10AM  
06:07AM  
01:52AM  
Feb-21-21 02:05PM  
Feb-19-21 12:49AM  
Feb-17-21 02:20PM  
01:00PM  
11:40AM  
09:29AM  
08:10AM  
07:10AM  
05:20AM  
Feb-16-21 10:01AM  
06:30AM  
Feb-15-21 07:00PM  
07:30AM  
Feb-14-21 05:12AM  
Feb-13-21 08:04PM  
07:10AM  
06:58AM  
Feb-12-21 08:56AM  
Feb-11-21 03:28PM  
11:19AM  
Feb-10-21 10:33AM  
Feb-09-21 01:33PM  
10:02AM  
08:09AM  
Feb-08-21 01:42PM  
Feb-05-21 11:19AM  
10:42AM  
08:04AM  
Feb-04-21 07:00PM  
06:00PM  
01:30PM  
12:37PM  
08:23AM  
Feb-03-21 07:22PM  
06:00PM  
02:08PM  
11:12AM  
10:46AM  
09:17AM  
09:07AM  
09:02AM  
07:31AM  
05:13AM  
03:21AM  
03:19AM  
02:40AM  
Feb-02-21 07:00PM  
07:00PM  
Feb-01-21 10:00AM  
05:08AM  
Jan-31-21 10:05PM  
05:02PM  
Jan-29-21 10:18AM  
09:43AM  
08:17AM  
Jan-28-21 04:40PM  
10:28AM  
Jan-27-21 10:08AM  
08:05AM  
06:45AM  
05:02AM  
Jan-26-21 09:55PM  
Jan-24-21 08:53AM  
Jan-23-21 09:14AM  
Jan-22-21 09:35AM  
08:27AM  
07:22AM  
12:19AM  
Jan-21-21 05:32PM  
05:30PM  
Jan-13-21 10:00AM  
Jan-12-21 03:26PM  
08:15AM  
03:00AM  
Jan-11-21 07:00AM  
06:41AM  
Jan-08-21 09:45AM  
06:02AM  
Jan-06-21 05:30PM  
Dec-31-20 06:01PM  
Dec-28-20 07:00AM  
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; Novartis; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; and CureVac. The company also has an agreement with Vir Biotechnology, Inc for research and development of new therapies for influenza and other respiratory viruses. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GLAXOSMITHKLINE PLCDirectorJul 21Buy18.00361,1116,499,9982,248,304Jul 22 04:18 PM
IDRA Idera Pharmaceuticals, Inc. daily Stock Chart
IDRA [NASD]
Idera Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.80 Insider Own1.70% Shs Outstand35.09M Perf Week8.37%
Market Cap169.49M Forward P/E- EPS next Y-0.74 Insider Trans3.42% Shs Float25.52M Perf Month-11.99%
Income-87.20M PEG- EPS next Q-0.23 Inst Own27.10% Short Float1.89% Perf Quarter22.69%
Sales0.00M P/S- EPS this Y-31.60% Inst Trans8.04% Short Ratio0.95 Perf Half Y154.26%
Book/sh-0.92 P/B- EPS next Y43.10% ROA-230.10% Target Price- Perf Year209.43%
Cash/sh0.84 P/C5.86 EPS next 5Y- ROE568.00% 52W Range0.81 - 6.14 Perf YTD34.06%
Dividend- P/FCF- EPS past 5Y4.80% ROI411.30% 52W High-19.87% Beta2.08
Dividend %- Quick Ratio4.60 Sales past 5Y81.80% Gross Margin- 52W Low505.17% ATR0.48
Employees36 Current Ratio4.60 Sales Q/Q- Oper. Margin- RSI (14)51.00 Volatility10.68% 8.86%
OptionableYes Debt/Eq- EPS Q/Q-51.80% Profit Margin- Rel Volume2.75 Prev Close4.36
ShortableYes LT Debt/Eq- EarningsMar 01 AMC Payout- Avg Volume504.39K Price4.92
Recom1.70 SMA20-2.64% SMA502.95% SMA20063.48% Volume1,388,850 Change12.84%
Sep-24-18Initiated Barclays Overweight $14
Aug-15-18Resumed JP Morgan Overweight $15
Nov-09-17Initiated H.C. Wainwright Buy $4
Apr-25-17Initiated Robert W. Baird Outperform $5
Mar-22-17Initiated JMP Securities Mkt Outperform
Feb-01-17Reiterated Wedbush Outperform $6
Jan-06-16Initiated Wedbush Outperform $6
Jun-15-15Initiated JP Morgan Overweight
Mar-03-14Initiated Cowen Outperform
Mar-24-10Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $10
Nov-21-08Initiated Noble Financial Buy
Oct-27-08Upgrade Susquehanna Financial Negative → Neutral
Aug-06-08Downgrade Canaccord Adams Buy → Hold
May-07-08Downgrade Janney Mntgmy Scott Buy → Neutral
May-02-08Downgrade Susquehanna Financial Neutral → Negative $11
Mar-01-21 04:35PM  
04:03PM  
Feb-28-21 02:49AM  
Feb-26-21 06:50AM  
Jan-11-21 06:02AM  
Dec-18-20 02:22AM  
Dec-17-20 08:45AM  
Dec-15-20 08:05AM  
Dec-04-20 08:34AM  
Nov-17-20 04:27PM  
Nov-03-20 07:10AM  
Oct-29-20 04:36PM  
Sep-28-20 08:45AM  
Sep-15-20 07:18AM  
Sep-10-20 10:13AM  
Aug-04-20 04:10PM  
Jul-15-20 08:05AM  
Jun-21-20 11:13PM  
Jun-02-20 08:15AM  
May-01-20 08:00AM  
Apr-30-20 04:35PM  
Apr-23-20 07:30AM  
Apr-21-20 07:30AM  
Apr-10-20 01:49PM  
Apr-07-20 04:05PM  
Mar-12-20 07:30AM  
Mar-06-20 11:14AM  
Mar-05-20 07:00AM  
Jan-14-20 07:00AM  
Dec-24-19 12:05PM  
09:24AM  
Dec-23-19 09:15AM  
Dec-16-19 04:39PM  
Nov-19-19 09:40AM  
Nov-06-19 04:01PM  
Nov-01-19 10:03AM  
Oct-25-19 10:46AM  
Oct-21-19 07:00AM  
Sep-30-19 07:30AM  
Sep-10-19 09:33AM  
Sep-04-19 07:00AM  
Aug-30-19 12:00PM  
Aug-17-19 04:20AM  
Aug-08-19 10:15AM  
09:00AM  
Aug-06-19 04:00PM  
Jul-25-19 10:33AM  
Jul-23-19 07:30AM  
Jul-10-19 01:46PM  
Jun-18-19 04:00PM  
May-10-19 09:35AM  
May-02-19 08:55PM  
04:30PM  
May-01-19 10:32AM  
Apr-29-19 08:34AM  
Apr-10-19 07:00AM  
Apr-02-19 07:00AM  
Mar-14-19 11:21AM  
Mar-07-19 01:55PM  
Mar-06-19 04:30PM  
Feb-27-19 07:00AM  
Jan-23-19 12:55PM  
Jan-18-19 01:08PM  
Jan-04-19 07:30AM  
Dec-18-18 04:05PM  
Dec-17-18 07:00AM  
Dec-14-18 07:00AM  
Dec-12-18 04:01PM  
Dec-11-18 07:20AM  
Dec-08-18 10:02AM  
Nov-27-18 01:01PM  
Nov-06-18 06:35PM  
05:32PM  
04:30PM  
Oct-19-18 06:00AM  
Oct-15-18 07:55AM  
Oct-11-18 08:34AM  
Sep-25-18 03:47PM  
Sep-18-18 04:01PM  
Sep-11-18 07:00AM  
Aug-30-18 07:30AM  
Aug-18-18 08:32AM  
Aug-14-18 07:35AM  
Aug-12-18 11:46AM  
Aug-10-18 08:00AM  
Aug-09-18 07:00AM  
Aug-07-18 03:38PM  
Aug-06-18 02:18PM  
Aug-02-18 06:05PM  
04:57PM  
04:30PM  
02:40PM  
Jul-27-18 11:58AM  
Jul-17-18 08:37AM  
Jul-16-18 07:00AM  
Jul-12-18 08:37AM  
Jul-11-18 05:33PM  
02:34PM  
01:26PM  
11:56AM  
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Exton, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kirby John J.Chief Financial OfficerJan 12Sale4.221,6937,15233,882Jan 12 07:12 PM
Tarka Elizabeth AnnChief Medical OfficerJan 12Sale4.191,7457,31018,255Jan 12 07:10 PM
Lim Bryant DavidSVP and General CounselJan 12Sale4.211,7117,20238,064Jan 12 07:08 PM
MILANO VINCENTPresident & CEOJan 12Sale4.203,21013,474208,611Jan 12 07:00 PM
Lim Bryant DavidSVP and General CounselJan 05Sale3.911,4655,72239,775Jan 11 08:15 PM
MILANO VINCENTPresident & CEOJan 05Sale3.912,74010,700211,821Jan 11 08:09 PM
Kirby John J.Chief Financial OfficerJan 05Sale3.908623,36235,575Jan 06 05:04 PM
MILANO VINCENTPresident & CEODec 22Sale4.3237,169160,525214,561Dec 22 06:45 PM
Pillar Invest Corp10% OwnerDec 11Buy1.8269,941127,2935,497,638Dec 15 06:00 PM
Pillar Invest Corp10% OwnerJul 13Buy1.72749,9931,289,9885,427,697Jul 15 06:16 PM
Pillar Invest Corp10% OwnerApr 07Buy1.523,039,5144,620,0616,260,832Apr 09 06:44 PM
NVS Novartis AG daily Stock Chart
NVS [NYSE]
Novartis AG
Index- P/E24.86 EPS (ttm)3.52 Insider Own9.30% Shs Outstand2.26B Perf Week-0.52%
Market Cap219.01B Forward P/E12.85 EPS next Y6.81 Insider Trans0.00% Shs Float2.11B Perf Month-5.81%
Income8.07B PEG3.02 EPS next Q1.64 Inst Own10.30% Short Float0.25% Perf Quarter-1.94%
Sales49.90B P/S4.39 EPS this Y14.20% Inst Trans1.55% Short Ratio2.53 Perf Half Y0.52%
Book/sh25.02 P/B3.50 EPS next Y6.54% ROA6.30% Target Price104.50 Perf Year4.16%
Cash/sh4.62 P/C18.94 EPS next 5Y8.23% ROE15.00% 52W Range69.18 - 98.52 Perf YTD-7.39%
Dividend3.38 P/FCF40.65 EPS past 5Y4.10% ROI8.80% 52W High-11.24% Beta0.58
Dividend %3.87% Quick Ratio0.70 Sales past 5Y-0.20% Gross Margin71.10% 52W Low26.41% ATR1.36
Employees105794 Current Ratio0.90 Sales Q/Q2.50% Oper. Margin20.30% RSI (14)38.85 Volatility1.26% 1.12%
OptionableYes Debt/Eq0.67 EPS Q/Q88.00% Profit Margin16.20% Rel Volume0.80 Prev Close85.91
ShortableYes LT Debt/Eq0.49 EarningsJan 26 BMO Payout87.10% Avg Volume2.05M Price87.45
Recom1.00 SMA20-2.42% SMA50-4.79% SMA200-0.54% Volume1,639,451 Change1.79%
Feb-01-21Downgrade Cowen Outperform → Market Perform $110 → $105
Jan-15-21Initiated Deutsche Bank Buy
Sep-29-20Initiated Berenberg Buy
Sep-10-20Upgrade UBS Neutral → Buy
Sep-01-20Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-15-20Upgrade Citigroup Neutral → Buy
Mar-10-20Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-20Downgrade Guggenheim Buy → Neutral
Apr-25-19Upgrade Liberum Hold → Buy
Apr-25-19Upgrade Guggenheim Neutral → Buy
Apr-10-19Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-02-19Downgrade JP Morgan Neutral → Underweight
Dec-11-18Resumed Jefferies Buy
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Underperform → Buy
May-29-18Downgrade HSBC Securities Buy → Hold
May-25-18Upgrade Credit Suisse Underperform → Neutral
Jan-25-18Reiterated Leerink Partners Outperform $93 → $100
Dec-06-17Downgrade BofA/Merrill Neutral → Underperform
Jul-26-17Upgrade Morgan Stanley Underweight → Overweight
Mar-01-21 09:51AM  
Feb-24-21 09:31AM  
Feb-19-21 07:45AM  
Feb-17-21 11:18AM  
07:26AM  
01:15AM  
Feb-16-21 01:23PM  
Feb-12-21 10:06AM  
08:56AM  
Feb-11-21 11:19AM  
07:00AM  
Feb-10-21 01:50PM  
Feb-09-21 10:16AM  
Feb-07-21 10:25AM  
Feb-04-21 06:00PM  
10:01AM  
07:21AM  
Jan-29-21 12:05PM  
10:22AM  
Jan-28-21 04:40PM  
06:36AM  
Jan-27-21 10:48AM  
Jan-26-21 10:01PM  
04:22PM  
09:38AM  
08:07AM  
07:56AM  
07:22AM  
07:00AM  
04:56AM  
02:20AM  
01:14AM  
01:00AM  
Jan-25-21 10:24AM  
Jan-23-21 08:10PM  
Jan-22-21 01:49PM  
Jan-21-21 10:29AM  
07:04AM  
Jan-20-21 12:15PM  
10:30AM  
Jan-15-21 09:11AM  
08:14AM  
Jan-14-21 04:35PM  
03:11PM  
Jan-12-21 04:31PM  
02:58PM  
08:15AM  
Jan-11-21 04:30PM  
Dec-31-20 08:52AM  
Dec-28-20 07:30AM  
07:00AM  
Dec-22-20 09:08AM  
Dec-21-20 10:16AM  
Dec-18-20 07:04PM  
05:08PM  
04:50PM  
07:34AM  
Dec-17-20 12:29PM  
09:25AM  
Dec-16-20 01:31PM  
07:15AM  
Dec-15-20 07:17PM  
10:37AM  
07:27AM  
01:15AM  
Dec-14-20 01:15AM  
Dec-11-20 09:29AM  
Dec-09-20 09:45AM  
09:00AM  
Dec-08-20 04:23PM  
10:00AM  
Dec-05-20 10:00AM  
Dec-04-20 12:30PM  
08:00AM  
Dec-03-20 04:33PM  
04:12AM  
Dec-02-20 04:09PM  
Nov-25-20 09:30AM  
Nov-24-20 08:12AM  
07:13AM  
01:00AM  
Nov-23-20 07:00PM  
Nov-20-20 11:20AM  
10:17AM  
09:44AM  
08:42AM  
07:37AM  
Nov-19-20 04:30PM  
10:00AM  
09:43AM  
01:15AM  
Nov-18-20 01:29AM  
Nov-16-20 01:54PM  
Nov-15-20 06:52AM  
Nov-13-20 10:00AM  
Nov-10-20 05:06PM  
04:46PM  
Nov-06-20 07:47AM  
02:00AM  
01:15AM  
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures LtdFormer 10% OwnerJun 30Buy17.00125,0002,125,0001,181,258Jul 02 04:16 PM
PFE Pfizer Inc. daily Stock Chart
PFE [NYSE]
Pfizer Inc.
IndexS&P 500 P/E20.23 EPS (ttm)1.67 Insider Own0.05% Shs Outstand5.56B Perf Week-1.66%
Market Cap189.16B Forward P/E11.00 EPS next Y3.06 Insider Trans-6.39% Shs Float5.55B Perf Month-6.05%
Income9.36B PEG3.01 EPS next Q0.79 Inst Own67.60% Short Float1.14% Perf Quarter-7.77%
Sales47.64B P/S3.97 EPS this Y-33.10% Inst Trans- Short Ratio1.50 Perf Half Y-6.10%
Book/sh11.71 P/B2.88 EPS next Y-7.21% ROA5.70% Target Price41.09 Perf Year6.37%
Cash/sh2.18 P/C15.48 EPS next 5Y6.73% ROE14.90% 52W Range26.42 - 43.08 Perf YTD-8.48%
Dividend1.56 P/FCF50.97 EPS past 5Y2.20% ROI7.60% 52W High-21.80% Beta0.67
Dividend %4.63% Quick Ratio1.00 Sales past 5Y-3.00% Gross Margin79.10% 52W Low27.51% ATR0.52
Employees78500 Current Ratio1.40 Sales Q/Q11.80% Oper. Margin15.70% RSI (14)30.31 Volatility1.44% 1.48%
OptionableYes Debt/Eq0.63 EPS Q/Q125.10% Profit Margin20.20% Rel Volume0.72 Prev Close33.49
ShortableYes LT Debt/Eq0.59 EarningsFeb 02 BMO Payout87.90% Avg Volume42.06M Price33.69
Recom2.60 SMA20-2.75% SMA50-6.66% SMA200-4.87% Volume30,129,803 Change0.60%
Feb-04-21Upgrade DZ Bank Hold → Buy $41
Dec-16-20Downgrade RBC Capital Mkts Outperform → Sector Perform $43 → $42
Nov-19-20Resumed Goldman Neutral $40
Nov-10-20Resumed Bernstein Mkt Perform $42
Oct-12-20Downgrade Atlantic Equities Overweight → Neutral $44 → $39
Sep-29-20Initiated Berenberg Hold $38
Jun-16-20Initiated SVB Leerink Mkt Perform $40
Feb-27-20Upgrade Standpoint Research Hold → Buy
Feb-27-20Initiated Barclays Equal Weight $36
Feb-06-20Initiated Mizuho Buy
Jan-07-20Initiated RBC Capital Mkts Outperform $46
Oct-17-19Resumed BofA/Merrill Neutral $37
Jul-30-19Downgrade Morgan Stanley Overweight → Equal-Weight $48 → $40
Jul-30-19Downgrade BofA/Merrill Buy → Neutral
Jun-04-19Resumed Morgan Stanley Overweight $48
Feb-20-19Resumed Citigroup Neutral $41
Jan-31-19Upgrade Credit Suisse Neutral → Outperform
Jan-31-19Upgrade Argus Hold → Buy
Jan-23-19Downgrade UBS Buy → Neutral
Dec-11-18Downgrade JP Morgan Overweight → Neutral
Mar-01-21 07:17PM  
05:14PM  
04:18PM  
04:16PM  
02:59PM  
01:56PM  
12:48PM  
12:45PM  
12:39PM  
11:07AM  
10:32AM  
10:27AM  
08:54AM  
08:38AM  
08:21AM  
07:56AM  
07:43AM  
07:15AM  
06:01AM  
06:00AM  
01:13AM  
Feb-28-21 04:57PM  
01:55PM  
09:37AM  
09:22AM  
06:01AM  
Feb-27-21 08:22PM  
06:39PM  
06:25PM  
06:19PM  
04:19PM  
02:34PM  
02:11PM  
08:17AM  
Feb-26-21 08:56PM  
07:24PM  
05:54PM  
05:44PM  
05:38PM  
05:08PM  
05:06PM  
01:46PM  
11:36AM  
10:47AM  
10:37AM  
10:06AM  
10:04AM  
08:47AM  
07:30AM  
06:45AM  
06:30AM  
06:30AM  
06:06AM  
06:00AM  
05:24AM  
05:00AM  
03:18AM  
03:00AM  
02:30AM  
02:04AM  
Feb-25-21 08:17PM  
06:00PM  
05:23PM  
05:15PM  
05:00PM  
04:52PM  
04:42PM  
02:42PM  
02:24PM  
12:46PM  
12:40PM  
12:07PM  
10:33AM  
09:00AM  
08:10AM  
08:08AM  
08:03AM  
08:00AM  
07:45AM  
07:39AM  
07:30AM  
07:10AM  
07:08AM  
07:03AM  
07:03AM  
07:00AM  
06:45AM  
06:45AM  
06:00AM  
05:07AM  
02:04AM  
12:13AM  
Feb-24-21 07:01PM  
06:06PM  
05:00PM  
04:42PM  
04:37PM  
04:12PM  
12:03PM  
11:35AM  
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Myovant Sciences Ltd., Akcea Therapeutics, Inc, Verily Life Sciences LLC, Merck KGaA, Valneva SE, IDEAYA Biosciences, Inc., BioNTech SE, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, BioInvent International AB, Sosei Group Corporation, LianBio, and Imcyse S.A. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SAHNI PAYALExecutive Vice PresidentFeb 25Option Exercise22.899,982228,48822,949Mar 01 04:10 PM
YOUNG JOHN DGroup PresidentFeb 25Option Exercise22.89163,3343,738,715579,791Mar 01 04:10 PM
SUSMAN SALLYExecutive Vice PresidentFeb 25Option Exercise22.8981,6671,869,358189,763Mar 01 04:10 PM
JOHNSON RADY AExecutive Vice PresidentFeb 25Option Exercise22.8937,658861,992100,937Mar 01 04:05 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 25Option Exercise22.8999,8162,284,788178,092Mar 01 04:05 PM
Hwang AngelaGroup PresidentFeb 25Option Exercise22.8922,686519,28342,927Mar 01 04:01 PM
BOURLA ALBERTChairman & CEOFeb 25Option Exercise22.86163,3343,733,815245,037Mar 01 03:58 PM
Carapezzi William R JRExecutive Vice PresidentFeb 25Option Exercise22.8927,222623,11271,553Mar 01 03:58 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 25Option Exercise22.89163,3343,738,715588,584Mar 01 03:58 PM
DAMICO JENNIFER B.SVP & ControllerFeb 25Option Exercise22.8912,477285,59919,781Mar 01 03:55 PM
BOURLA ALBERTChairman & CEONov 09Sale41.94132,5085,557,38678,273Nov 10 05:55 PM
SUSMAN SALLYExecutive Vice PresidentNov 09Sale41.9443,6621,831,184108,096Nov 10 05:55 PM
PFIZER INC10% OwnerOct 27Buy10.001,200,00012,000,00027,349,211Oct 29 05:44 PM
BLAYLOCK RONALD EDirectorAug 06Buy38.5513,000501,08513,000Aug 10 08:07 AM
DAMICO JENNIFER B.SVP & ControllerJun 05Sale36.132,18178,8007,542Jun 08 04:29 PM
Dolsten MikaelPresident R&DMay 18Sale37.7895,3533,602,681174,918May 19 05:37 PM
DAMICO JENNIFER B.SVP & ControllerApr 29Sale38.352,18183,6419,647May 01 03:56 PM
JOHNSON RADY AExecutive Vice PresidentApr 29Sale38.3613,125503,47563,940May 01 03:56 PM
ROGERS DAWNExecutive Vice PresidentApr 29Sale38.1313,000495,6904,823May 01 03:56 PM
LANKLER DOUGLAS MExecutive Vice PresidentApr 29Sale37.8565,0002,460,37278,276May 01 03:56 PM
PFIZER INC10% OwnerMar 16Buy16.00312,5005,000,0001,481,719Mar 16 07:15 PM